Silence Therapeutics (SLN) shares fell more than 11% in midday Tuesday trading after Goldman Sachs initiated coverage of the stock at sell with a price target of $6.
Trading volume stood at 445,000 shares versus a daily average of 585,280 shares.
Price: 4.36, Change: -0.56, Percent Change: -11.36